A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing | Zendy

Ganesh Prasanna | Zendy; Luciana Ferrara | Zendy; Christopher M. Adams | Zendy; Takeru Ehara | Zendy; Byron Li | Zendy; Louis Yang | Zendy; Chuanxi Xiang | Zendy; Christopher NgThowHing | Zendy; Sean Kim | Zendy; Christopher Towler | Zendy; Todd Topley | Zendy; Cale McAllister | Zendy; Malay Ghosh | Zendy; Ronald Newton | Zendy; Rebecca C. Stacy | Zendy; Dennis S. Rice | Zendy; Muneto Mogi | Zendy

Open Access

A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing

Author(s) -

Ganesh Prasanna,

Luciana Ferrara,

Christopher M. Adams,

Takeru Ehara,

Byron Li,

Louis Yang,

Chuanxi Xiang,

Christopher NgThowHing,

Sean Kim,

Christopher Towler,

Todd Topley,

Cale McAllister,

Malay Ghosh,

Ronald Newton,

Rebecca C. Stacy,

Dennis S. Rice,

Muneto Mogi

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-23772

Subject(s) - glaucoma , intraocular pressure , medicine , trabecular meshwork , pharmacology , dosing , tolerability , activator (genetics) , nitric oxide , ocular hypertension , ophthalmology , adverse effect , receptor

The nitric oxide/soluble guanylate cyclase/protein kinase G (NO/sGC/PKG) is known to be involved in the regulation of intraocular pressure (IOP) and may be dysregulated in glaucoma. The purpose is to demonstrate that the sGC activator MGV354 lowers IOP in a monkey model of glaucoma and could be considered as a possible new clinical drug candidate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research